Croft N M, Marshall T G, Ferguson A
Department of Medicine, University of Edinburgh, Western General Hospital, UK.
Lancet. 1995 Nov 11;346(8985):1265-7. doi: 10.1016/s0140-6736(95)91864-7.
We used a whole-gut perfusion technique to study subclinical gut inflammation in children with cystic fibrosis (18 elective tests, three lavages to treat distal intestinal obstruction syndrome); and in 12 control children with constipation or pre-colonoscopy. We assayed for haemoglobin, IgG, albumin, alpha-1-antitrypsin, granulocyte elastase, interleukin-1 beta (IL-1 beta) and IL-8 concentrations in whole-gut lavage fluid. Results for two children with distal intestinal obstruction syndrome, the only children in the series taking Nutrizym 22, were strikingly abnormal. This new test has revealed subclinical gut mucosal inflammation in a minority of CF children, for which distal intestinal obstruction syndrome, Nutrizym 22 treatment, or both, may be risk factors.
我们采用全肠道灌注技术，对患有囊性纤维化的儿童（18次选择性检测，3次灌洗以治疗远端肠梗阻综合征）以及12名患有便秘或进行结肠镜检查前的对照儿童进行亚临床肠道炎症研究。我们检测了全肠道灌洗液中的血红蛋白、免疫球蛋白G、白蛋白、α-1抗胰蛋白酶、粒细胞弹性蛋白酶、白细胞介素-1β（IL-1β）和IL-8浓度。在该系列中仅有的两名服用Nutrizym 22的患有远端肠梗阻综合征的儿童，其检测结果异常显著。这项新检测揭示了少数囊性纤维化儿童存在亚临床肠道黏膜炎症，而远端肠梗阻综合征、Nutrizym 22治疗或两者均可能是其危险因素。
